Digestive tract hemorrhage due to complications with gastrointestinal stromal tumor treated with sunitinib: A case report

Oncology Letters

Volumn 5, Issue 2, 2013, Pages 699-701

  Liu, Yan ^a   Zhang, He Long ^b   Zhang, Ye ^b   Mei, Jia Zhuan ^a   Lin, Hong Wei ^a   Guo, Yan Wei ^a   Li, Rui Jun ^a   Meng, Xiang Rui ^a   Liu, Gui Ju ^a   Li, Min ^a   Xiao, Peng ^a   Bai, Hua ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Gastrointestinal stromal tumor; Hemorrhage; Sunitinib

Indexed keywords

HEMOGLOBIN; SUNITINIB;

AGED; ANOREXIA; ARTICLE; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM HEMORRHAGE; DRUG DOSE REDUCTION; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEMATEMESIS; HUMAN; HUMAN TISSUE; HUNGER; IMMUNOHISTOCHEMISTRY; MELENA; NAUSEA; RECTUM HEMORRHAGE; SOMNOLENCE; VOMITING;

EID: 84871579482     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1050     Document Type: Article

References (30)

1. Hauber AB, Gonzalez JM, Coombs J, et al: Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST). Patient Prefer Adherence 5: 307-314, 2011.
2. Di Scioscio V, Greco L, Pallotti MC, et al: Three cases of bone metastases in patients with gastrointestinal stromal tumors. Rare Tumors 3: e17, 2011.
3. Afuwape OO, Irabor DO and Ladipo JK: Gastrointestinal stromal tumour in Ibadan, Nigeria: a case report and review of current treatment. Afr Health Sci 11: 134-138, 2011.
4. Issar P, Dwivedi MK, Issar SK, Pal RK and DewanaganL: Malignant gastrointestinal stromal tumours. Indian J Radiol Imaging 16: 65-67, 2006.
5. Wingen CB, Pauwels PA, Debiec-Rychter M, van Gemert WG, and Vos MC: Uterine gastrointestinal stromal tumours (GIST). Gynecol Oncol 97: 970-972, 2005.
6. DeMatteo RP, Lewis JJ, Leung D, et al: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231: 51-58, 2000.
7. Chen YY, Yeh CN, Cheng CT, et al: Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World J Gastroenterol 17: 2113-2119, 2011.
8. Kindblom LG, Remotti HE, Aldenborg F, et al: Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152: 1259-1269, 1998.
9. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580, 1998.
10. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastronitestinal stromal tumors. N Engl J Med 347: 472-480, 2002.
11. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1338, 2006.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000.
13. Choi H, Charnsangavej C, Faria SC, et al: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25: 1753-1759, 2007.
14. Miettinen M and Lasota J: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130: 1466-1478, 2006.
15. Daniels M, Lurkin I, Pauli R, Erbstösser E, et al: Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett 312: 43-54, 2011.
16. Miettinen M and Lasota J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23: 70-83, 2006.
17. Corless CL, Fletcher JA, Heinrich MC, et al: Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813-3825, 2004.
18. Bucher P, Villiger P, Egger JF, et al: Management of gastrointestinal stromal tumours: from diagnosis to treatment. Swiss Med Wkly 134: 145-153, 2004.
19. Annaberdyev S, Gibbons J and Hardacre JM: Dramatic response of a gastrointestinal stromal tumour to neoadjuvant imatinib therapy. World J Surg Oncol 7: 30, 2009.
20. Dematteo RP, Ballman KV, Antonescu CR, et al: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373: 1097-104, 2009.
21. Ibrahim HH, Ahmad MS, Eskaf WA, et al: Malignant gastrointestinal stromal tumor of the tongue: case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111: e24-e29, 2011.
22. Nowain A, Bhakta H, Pais S, et al: Gastrointestinal stromal tumors: clinical profile, pathogenesis, treatment strategies and prognosis. J Gastroenterol Hepatol 20: 818-824, 2005.
23. Arru JM and Richardson JD: Gastrointestinal stromal tumors: pathogenesis and current treatment. J Ky Med Assoc 103: 211-215, 2005.
24. Osusky KL, Hallahan DE, Fu A, et al: The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7: 225-233, 2004.
25. Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471-478, 2003.
26. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-337, 2003.
27. Murray LJ, Abrams TJ, Long KR, et al: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20: 757-766, 2003.
28. O'Farrell AM, Abrams TJ, Yuen HA, et al: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101: 3597-3605, 2003.
29. Schueneman AJ, Himmelfarb E, Geng L, et al: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63: 4009-4016, 2003.
30. Joensuu H, Trent JC and Reichardt P: Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev Feb 37: 75-88, 2011.